Tirzepatide non-response with subsequent semaglutide response in class 2 obesity

More on GLP-1 and incretin signalling

• Survodutide reduces weight in adults with diabetes and obesity

  The New England Journal of Medicine · 4 Oct 2026

• Retatrutide reduces weight and pain in adults with obesity

  The New England Journal of Medicine · 4 Oct 2026

• Retatrutide reduces bodyweight in obesity and type 2 diabetes

  Lancet · 4 Oct 2026

• Semaglutide may protect kidneys by reducing vascular resistance

  Nature Medicine · 4 Oct 2026